The term is found again in Thomas Willis (1621–1675) influential De anima brutorum (1672), where lethargy (pathological sleep), coma (heavy sleeping), carus (deprivation of the senses) and apoplexy (into which carus could turn and which he localized in the white matter) are mentioned. The term carus is also derived from Greek, where it can be found in the roots of several words meaning soporific or sleepy. It can still be found in the root of the term carotid. Thomas Sydenham (1624–89) mentioned the term coma in several cases of fever (Sydenham, 1685). Signs and symptoms
General symptoms of a person in a comatose state are:

Inability to voluntarily open the eyes
A non-existent sleep-wake cycle
Lack of response to physical (painful) or verbal stimuli
Depressed brainstem reflexes, such as pupils not responding to light
Irregular breathing
Scores between 3 and 8 on the Glasgow Coma Scale

Causes
Many types of problems can cause a coma. Forty percent of comatose states result from drug poisoning. Certain drug use under certain conditions can damage or weaken the synaptic functioning in the ascending reticular activating system (ARAS) and keep the system from properly functioning to arouse the brain. Secondary effects of drugs, which include abnormal heart rate and blood pressure, as well as abnormal breathing and sweating, may also indirectly harm the functioning of the ARAS and lead to a coma. Given that drug poisoning is the cause for a large portion of patients in a coma, hospitals first test all comatose patients by observing pupil size and eye movement, through the vestibular-ocular reflex. (See Diagnosis below.
In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.In January 2016, a biologics license application (BLA) was submitted to the US FDA. Approval followed in February 2017. References
External links
"Brodalumab". Drug Information Portal. U.S. National Library of Medicine.